2015年9月7日から11日にかけて、米国サンフランシスコにおいて第25回国際リンパ学会(25th World Congress of Lymphology)が開催されました。
36ヶ国から約900名の参加があり、弊社会長関根暉彬が、がん免疫治療に関するミニセミナーで講演を行いました。
その後、セミナーの他の演者と共に米国における免疫治療の現状と課題について、活発な議論がなされました。今後もこのような機会を通して、国内外の研究者と共に免疫治療の発展に貢献していきたいと思います。

関根会長の講演タイトル:
”Expanded and Activated Autologous T-lymphocytes Effective to the Treatment of Cancers and Chronic Viral Infections”

 

オープニングセッションの様子

オープニングセッションの様子

関根会長の講演

関根会長の講演

ミニセミナーの演者の皆さんと船本社長  (左から)Dr. Stanley Leong (本学会の議長、UCSF名誉教授)   Dr. Kevin Kim (Director, California Pacific Medical Center) ㈱リンフォテック会長 関根暉彬 Dr. Cassian Yee (UT MD Anderson Cancer Center教授) ㈱リンフォテック社長 船本宏幸

ミニセミナーの演者の皆さんと船本社長
 (左から)Dr. Stanley Leong (本学会の議長、UCSF名誉教授)
Dr. Kevin Kim (Director, California Pacific Medical Center)
㈱リンフォテック会長 関根暉彬
Dr. Cassian Yee (UT MD Anderson Cancer Center教授)
㈱リンフォテック社長 船本宏幸

EXPANDED AND ACTIVATED AUTOLOGOUS
T-LYMPHOCYTES EFFECTIVE TO THE TREATMENT OF CANCERS AND CHRONIC VIRAL INFECTIONS

TERUAKI SEKINE, LYMPHOTEC INC., TOKYO, JAPAN

 Peripheral blood contains memory T cells specific to cancers and viruses. These memory T cells can be expanded and activated. We describe the applications and results using the method developed by us at the National Cancer Center in Japan.
 Mononuclear cells are separated from approximately 30ml of peripheral blood and cultured with insoluble OKT3 and IL-2 for 3-5 days, followed by additional culture in a medium containing only IL-2 for 9-11 days.
 By this method, the number of T-cells can be expanded up to 1,000 times the original number. Most of the T cells are central memory T cells and effector memory T cells expressing HLA-DR, suggesting that those are activated T cells.
The expanded autologous T cells are applicable to point of care treatment of cancers and act to control tumor size and inhibit recurrence after surgery.
The cells are also effective for the treatment of chronic viral infections and viral infection or relapse of leukemia as a DLI after blood stem cell transplantation. Expanded and purified CD4 infusion is effective as DLI. In peripheral blood of the patients with chronic active EB virus infectious disease (CAEBV), over 1% of T cells showed EB virus specific activity, although clinical symptoms were not improved. After infusion of activated autologous T-lymphocytes to CAEBV, these patients responded remarkably. It is presumed that, in these patients, the activation step of T memory cells was inhibited and this is the reason why infusion of activated autologous T lymphocytes was effective.
Up to now, over 10,000 patients have received infusions of activated autologous T lymphocytes in Japan for the treatment of cancers.